Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Rectal Neoplasms | 32 | 2024 | 1183 | 3.220 |
Why?
|
Colorectal Surgery | 7 | 2020 | 125 | 2.640 |
Why?
|
Colectomy | 12 | 2021 | 699 | 1.840 |
Why?
|
Anus Neoplasms | 9 | 2024 | 336 | 1.590 |
Why?
|
Digestive System Surgical Procedures | 7 | 2020 | 584 | 0.850 |
Why?
|
Postoperative Complications | 24 | 2025 | 15889 | 0.850 |
Why?
|
Perineum | 6 | 2024 | 211 | 0.820 |
Why?
|
Rectum | 11 | 2023 | 900 | 0.810 |
Why?
|
Perioperative Care | 4 | 2019 | 1045 | 0.810 |
Why?
|
Adenocarcinoma | 18 | 2020 | 6401 | 0.800 |
Why?
|
Length of Stay | 11 | 2025 | 6525 | 0.700 |
Why?
|
Abdomen | 6 | 2019 | 1137 | 0.660 |
Why?
|
Abdominal Muscles | 1 | 2019 | 172 | 0.630 |
Why?
|
Colon | 8 | 2020 | 1804 | 0.600 |
Why?
|
Dendritic Cell Sarcoma, Interdigitating | 1 | 2017 | 3 | 0.590 |
Why?
|
Health Plan Implementation | 1 | 2020 | 338 | 0.560 |
Why?
|
Bupivacaine | 1 | 2019 | 413 | 0.530 |
Why?
|
Neoplasm Staging | 25 | 2023 | 11262 | 0.510 |
Why?
|
Colonic Neoplasms | 11 | 2021 | 2543 | 0.500 |
Why?
|
Appendiceal Neoplasms | 4 | 2019 | 155 | 0.470 |
Why?
|
Anal Canal | 5 | 2019 | 375 | 0.460 |
Why?
|
Diverticulitis | 3 | 2022 | 187 | 0.450 |
Why?
|
Infection Control | 1 | 2020 | 984 | 0.420 |
Why?
|
Carcinoid Tumor | 3 | 2019 | 224 | 0.420 |
Why?
|
Constipation | 2 | 2015 | 570 | 0.420 |
Why?
|
Tissue Adhesions | 2 | 2013 | 223 | 0.410 |
Why?
|
Appendectomy | 4 | 2020 | 443 | 0.410 |
Why?
|
Carcinoma, Squamous Cell | 4 | 2021 | 4064 | 0.380 |
Why?
|
Colorectal Neoplasms | 12 | 2021 | 6982 | 0.370 |
Why?
|
Venous Thromboembolism | 2 | 2021 | 1880 | 0.350 |
Why?
|
Pain, Postoperative | 2 | 2020 | 1765 | 0.340 |
Why?
|
Analgesics, Opioid | 3 | 2020 | 3837 | 0.320 |
Why?
|
Stress, Physiological | 1 | 2017 | 1410 | 0.320 |
Why?
|
Academic Medical Centers | 2 | 2017 | 2784 | 0.320 |
Why?
|
Abdominal Pain | 2 | 2015 | 1070 | 0.310 |
Why?
|
Adenomatous Polyposis Coli | 2 | 2021 | 219 | 0.310 |
Why?
|
Neuroendocrine Tumors | 3 | 2019 | 657 | 0.300 |
Why?
|
Survival Rate | 20 | 2021 | 12873 | 0.290 |
Why?
|
Brachytherapy | 3 | 2007 | 1224 | 0.280 |
Why?
|
Retrospective Studies | 35 | 2025 | 81892 | 0.280 |
Why?
|
Surgical Flaps | 4 | 2024 | 1682 | 0.270 |
Why?
|
Informed Consent | 1 | 2013 | 1010 | 0.270 |
Why?
|
Hemorrhoids | 2 | 1999 | 19 | 0.270 |
Why?
|
Hyperthermia, Induced | 2 | 2021 | 416 | 0.270 |
Why?
|
Adenocarcinoma, Mucinous | 3 | 2019 | 526 | 0.270 |
Why?
|
Treatment Refusal | 2 | 2020 | 432 | 0.270 |
Why?
|
Radiation Injuries | 2 | 2004 | 1203 | 0.270 |
Why?
|
Middle Aged | 63 | 2025 | 223740 | 0.270 |
Why?
|
Neoadjuvant Therapy | 3 | 2023 | 2909 | 0.270 |
Why?
|
Postoperative Period | 3 | 2020 | 1830 | 0.270 |
Why?
|
Databases, Factual | 8 | 2021 | 8095 | 0.270 |
Why?
|
Humans | 111 | 2025 | 768887 | 0.260 |
Why?
|
Surgical Wound Infection | 4 | 2019 | 1546 | 0.260 |
Why?
|
Neoplasm Recurrence, Local | 11 | 2020 | 9442 | 0.250 |
Why?
|
Combined Modality Therapy | 13 | 2021 | 8559 | 0.250 |
Why?
|
Crohn Disease | 3 | 2020 | 2297 | 0.240 |
Why?
|
Ileum | 4 | 2020 | 558 | 0.240 |
Why?
|
Interleukin-23 | 1 | 2006 | 202 | 0.240 |
Why?
|
Aged | 45 | 2025 | 171790 | 0.240 |
Why?
|
Urinary Fistula | 1 | 2004 | 44 | 0.230 |
Why?
|
Opioid-Related Disorders | 1 | 2019 | 2189 | 0.230 |
Why?
|
Triazines | 1 | 2006 | 311 | 0.230 |
Why?
|
Homeodomain Proteins | 3 | 2020 | 2431 | 0.230 |
Why?
|
Peritoneal Neoplasms | 2 | 2021 | 714 | 0.220 |
Why?
|
Rectal Fistula | 1 | 2004 | 76 | 0.220 |
Why?
|
Male | 65 | 2025 | 365249 | 0.220 |
Why?
|
Interleukin-12 | 1 | 2006 | 577 | 0.220 |
Why?
|
Hospitalization | 2 | 2020 | 10845 | 0.220 |
Why?
|
Endoscopy, Gastrointestinal | 2 | 2018 | 888 | 0.210 |
Why?
|
Morpholines | 1 | 2006 | 584 | 0.210 |
Why?
|
Clinical Protocols | 4 | 2025 | 1445 | 0.210 |
Why?
|
Laparoscopy | 6 | 2018 | 2055 | 0.210 |
Why?
|
Appendicitis | 3 | 2019 | 689 | 0.210 |
Why?
|
Microsurgery | 1 | 2008 | 803 | 0.200 |
Why?
|
Iliac Artery | 1 | 2004 | 344 | 0.200 |
Why?
|
Female | 63 | 2025 | 397464 | 0.200 |
Why?
|
Colostomy | 2 | 2017 | 106 | 0.200 |
Why?
|
Patient Readmission | 6 | 2025 | 3313 | 0.190 |
Why?
|
Ileostomy | 2 | 2017 | 122 | 0.190 |
Why?
|
Operating Rooms | 2 | 2020 | 793 | 0.180 |
Why?
|
Economics, Nursing | 1 | 2020 | 7 | 0.180 |
Why?
|
Colonic Diseases | 2 | 2019 | 204 | 0.180 |
Why?
|
United States | 21 | 2025 | 73180 | 0.170 |
Why?
|
Incidence | 9 | 2021 | 21545 | 0.170 |
Why?
|
Duodenal Neoplasms | 1 | 2020 | 114 | 0.170 |
Why?
|
Hemorrhage | 2 | 2004 | 3465 | 0.170 |
Why?
|
Economics, Pharmaceutical | 1 | 2020 | 88 | 0.170 |
Why?
|
Intestinal Neoplasms | 2 | 2020 | 314 | 0.170 |
Why?
|
Follow-Up Studies | 19 | 2019 | 39394 | 0.170 |
Why?
|
Lymph Nodes | 3 | 2020 | 3473 | 0.160 |
Why?
|
Resuscitation Orders | 1 | 2021 | 271 | 0.160 |
Why?
|
Healthcare Disparities | 3 | 2019 | 3421 | 0.160 |
Why?
|
Sigmoidoscopy | 1 | 2019 | 150 | 0.160 |
Why?
|
Reed-Sternberg Cells | 1 | 2019 | 78 | 0.160 |
Why?
|
Orthopedic Equipment | 1 | 1998 | 22 | 0.160 |
Why?
|
Chemoprevention | 1 | 2021 | 326 | 0.160 |
Why?
|
Ileal Diseases | 1 | 2019 | 70 | 0.160 |
Why?
|
Diagnosis-Related Groups | 1 | 2020 | 447 | 0.150 |
Why?
|
Portasystemic Shunt, Transjugular Intrahepatic | 1 | 1999 | 96 | 0.150 |
Why?
|
Inflammatory Bowel Diseases | 5 | 2020 | 2445 | 0.150 |
Why?
|
Omentum | 1 | 2019 | 168 | 0.150 |
Why?
|
Carcinoma, Large Cell | 1 | 2019 | 114 | 0.150 |
Why?
|
Treatment Outcome | 20 | 2020 | 65485 | 0.150 |
Why?
|
Goals | 1 | 2023 | 716 | 0.150 |
Why?
|
Varicose Veins | 1 | 1999 | 158 | 0.150 |
Why?
|
Preoperative Period | 1 | 2020 | 565 | 0.150 |
Why?
|
Time Factors | 10 | 2019 | 40266 | 0.150 |
Why?
|
Equipment and Supplies | 1 | 2020 | 274 | 0.140 |
Why?
|
Coccyx | 1 | 1997 | 13 | 0.140 |
Why?
|
Hypertension, Portal | 1 | 1999 | 230 | 0.140 |
Why?
|
Hernia, Inguinal | 1 | 2020 | 225 | 0.140 |
Why?
|
Abdominal Abscess | 1 | 2018 | 153 | 0.140 |
Why?
|
Chemotherapy, Adjuvant | 4 | 2019 | 3554 | 0.140 |
Why?
|
Intraoperative Complications | 1 | 2004 | 1176 | 0.140 |
Why?
|
Databases as Topic | 1 | 2019 | 475 | 0.140 |
Why?
|
Pelvis | 2 | 2024 | 738 | 0.140 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 5 | 2021 | 11886 | 0.140 |
Why?
|
Carcinoma, Small Cell | 1 | 2019 | 419 | 0.130 |
Why?
|
Hyaluronic Acid | 2 | 2013 | 488 | 0.130 |
Why?
|
Military Medicine | 1 | 2018 | 185 | 0.130 |
Why?
|
Leiomyosarcoma | 1 | 2020 | 425 | 0.130 |
Why?
|
Disease-Free Survival | 5 | 2015 | 6856 | 0.130 |
Why?
|
Aged, 80 and over | 18 | 2020 | 59738 | 0.130 |
Why?
|
Liposomes | 1 | 2019 | 792 | 0.130 |
Why?
|
Prognosis | 12 | 2020 | 30044 | 0.130 |
Why?
|
Adult | 31 | 2023 | 223818 | 0.130 |
Why?
|
Malnutrition | 1 | 2022 | 631 | 0.130 |
Why?
|
Patient Selection | 4 | 2020 | 4265 | 0.120 |
Why?
|
Anastomosis, Surgical | 5 | 2019 | 994 | 0.120 |
Why?
|
Morphine | 1 | 2019 | 658 | 0.120 |
Why?
|
Lymphoproliferative Disorders | 1 | 2019 | 529 | 0.120 |
Why?
|
Mesothelioma | 1 | 2021 | 811 | 0.120 |
Why?
|
Intraoperative Care | 1 | 1999 | 771 | 0.120 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2019 | 342 | 0.120 |
Why?
|
Documentation | 1 | 2021 | 917 | 0.120 |
Why?
|
Propensity Score | 2 | 2020 | 1968 | 0.120 |
Why?
|
Drug Utilization | 1 | 2020 | 1191 | 0.110 |
Why?
|
Early Detection of Cancer | 2 | 2019 | 3238 | 0.110 |
Why?
|
Bacteria, Aerobic | 1 | 1993 | 24 | 0.110 |
Why?
|
Neoplasm Invasiveness | 4 | 2020 | 3629 | 0.110 |
Why?
|
Antimetabolites, Antineoplastic | 3 | 2008 | 647 | 0.110 |
Why?
|
Bacteria, Anaerobic | 1 | 1993 | 71 | 0.110 |
Why?
|
Peritoneal Cavity | 1 | 2013 | 135 | 0.110 |
Why?
|
Clinical Trials as Topic | 3 | 2006 | 8055 | 0.110 |
Why?
|
Radiotherapy, Adjuvant | 5 | 1999 | 1793 | 0.110 |
Why?
|
Facility Design and Construction | 1 | 2013 | 85 | 0.110 |
Why?
|
Specialties, Surgical | 1 | 2017 | 393 | 0.100 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2019 | 617 | 0.100 |
Why?
|
Surgery Department, Hospital | 1 | 2013 | 176 | 0.100 |
Why?
|
Cytosine | 1 | 2013 | 213 | 0.100 |
Why?
|
Fluorouracil | 3 | 2008 | 1655 | 0.100 |
Why?
|
Ileus | 2 | 2016 | 66 | 0.100 |
Why?
|
Range of Motion, Articular | 1 | 1998 | 1599 | 0.090 |
Why?
|
Mitomycin | 2 | 2019 | 262 | 0.090 |
Why?
|
Lymphoma | 1 | 2020 | 1900 | 0.090 |
Why?
|
Quality Improvement | 4 | 2019 | 3856 | 0.090 |
Why?
|
Health Services Accessibility | 2 | 2019 | 5520 | 0.090 |
Why?
|
Cell Differentiation | 3 | 2020 | 11684 | 0.090 |
Why?
|
Joint Instability | 1 | 1998 | 803 | 0.090 |
Why?
|
Liver Neoplasms | 5 | 2021 | 4363 | 0.090 |
Why?
|
Costs and Cost Analysis | 1 | 2016 | 1669 | 0.090 |
Why?
|
Survival Analysis | 7 | 2020 | 10115 | 0.090 |
Why?
|
Postoperative Care | 1 | 2016 | 1481 | 0.090 |
Why?
|
Knee Joint | 1 | 1998 | 1685 | 0.080 |
Why?
|
Monocytes | 2 | 2021 | 2603 | 0.080 |
Why?
|
Intestinal Obstruction | 2 | 2006 | 433 | 0.080 |
Why?
|
Arrhythmias, Cardiac | 1 | 2019 | 2258 | 0.080 |
Why?
|
Cohort Studies | 6 | 2021 | 41800 | 0.080 |
Why?
|
Military Personnel | 1 | 2018 | 1264 | 0.080 |
Why?
|
Anesthesia | 1 | 2020 | 1596 | 0.080 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2019 | 1189 | 0.080 |
Why?
|
Hospitals, Community | 2 | 2021 | 365 | 0.080 |
Why?
|
Decision Support Techniques | 1 | 2019 | 2008 | 0.080 |
Why?
|
Tumor Microenvironment | 2 | 2020 | 3951 | 0.080 |
Why?
|
Proportional Hazards Models | 5 | 2020 | 12563 | 0.080 |
Why?
|
Heart-Assist Devices | 1 | 2019 | 1292 | 0.080 |
Why?
|
Antibiotics, Antineoplastic | 2 | 2019 | 682 | 0.070 |
Why?
|
Risk Factors | 11 | 2020 | 74971 | 0.070 |
Why?
|
Immunity, Innate | 1 | 2020 | 3080 | 0.070 |
Why?
|
Intestinal Mucosa | 3 | 2014 | 3047 | 0.070 |
Why?
|
Health Status Disparities | 1 | 2019 | 1886 | 0.070 |
Why?
|
Acute Kidney Injury | 1 | 2019 | 1936 | 0.070 |
Why?
|
Salvage Therapy | 2 | 2019 | 1277 | 0.070 |
Why?
|
Radiotherapy Dosage | 2 | 2008 | 2920 | 0.070 |
Why?
|
Remission Induction | 2 | 2006 | 2411 | 0.070 |
Why?
|
Interleukin-2 | 1 | 2013 | 1895 | 0.070 |
Why?
|
Chewing Gum | 1 | 2006 | 40 | 0.070 |
Why?
|
Intestine, Small | 3 | 2020 | 1218 | 0.070 |
Why?
|
Primary Health Care | 1 | 2023 | 4748 | 0.070 |
Why?
|
Carboxymethylcellulose Sodium | 1 | 2006 | 38 | 0.060 |
Why?
|
Hydrazones | 1 | 2006 | 105 | 0.060 |
Why?
|
Prostatic Neoplasms | 2 | 2007 | 11229 | 0.060 |
Why?
|
Medicaid | 1 | 2019 | 2843 | 0.060 |
Why?
|
Neoplasm Metastasis | 3 | 2019 | 4926 | 0.060 |
Why?
|
Sepsis | 1 | 2018 | 2609 | 0.060 |
Why?
|
Carcinoma | 3 | 2007 | 2340 | 0.060 |
Why?
|
Preoperative Care | 1 | 2013 | 2258 | 0.060 |
Why?
|
Prospective Studies | 13 | 2019 | 54950 | 0.060 |
Why?
|
Dermoid Cyst | 1 | 2004 | 92 | 0.050 |
Why?
|
Muscle, Skeletal | 1 | 1999 | 4980 | 0.050 |
Why?
|
Logistic Models | 5 | 2020 | 13317 | 0.050 |
Why?
|
Macrophages | 1 | 2018 | 5800 | 0.050 |
Why?
|
Age Factors | 4 | 2020 | 18454 | 0.050 |
Why?
|
Pancreatic Neoplasms | 2 | 2020 | 5443 | 0.050 |
Why?
|
Tomography, Spiral Computed | 1 | 2004 | 274 | 0.050 |
Why?
|
Dendritic Cells | 1 | 2014 | 2748 | 0.050 |
Why?
|
Case-Control Studies | 1 | 2020 | 22294 | 0.050 |
Why?
|
Lipoma | 1 | 2004 | 296 | 0.050 |
Why?
|
Reoperation | 3 | 2018 | 4342 | 0.050 |
Why?
|
Cell Line, Tumor | 4 | 2021 | 17174 | 0.050 |
Why?
|
Fallopian Tube Neoplasms | 1 | 2004 | 329 | 0.050 |
Why?
|
Multivariate Analysis | 4 | 2020 | 12093 | 0.050 |
Why?
|
Liver Transplantation | 1 | 1993 | 2403 | 0.050 |
Why?
|
Anticoagulants | 1 | 2016 | 4850 | 0.040 |
Why?
|
Cell Compartmentation | 1 | 2021 | 383 | 0.040 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2004 | 592 | 0.040 |
Why?
|
Melanoma | 1 | 2018 | 5709 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2004 | 878 | 0.040 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2000 | 187 | 0.040 |
Why?
|
Microsatellite Repeats | 1 | 2021 | 785 | 0.040 |
Why?
|
Guideline Adherence | 1 | 2009 | 2240 | 0.040 |
Why?
|
Critical Pathways | 1 | 2023 | 476 | 0.040 |
Why?
|
Pelvic Exenteration | 1 | 1999 | 22 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2021 | 8664 | 0.040 |
Why?
|
Perioperative Period | 1 | 2020 | 252 | 0.040 |
Why?
|
Rectal Diseases | 1 | 2000 | 142 | 0.040 |
Why?
|
Collateral Ligaments | 1 | 1998 | 34 | 0.040 |
Why?
|
Hepatic Encephalopathy | 1 | 1999 | 144 | 0.040 |
Why?
|
Cecum | 1 | 2019 | 231 | 0.040 |
Why?
|
DNA Mismatch Repair | 1 | 2021 | 432 | 0.040 |
Why?
|
Administration, Oral | 1 | 2006 | 4042 | 0.040 |
Why?
|
Microsatellite Instability | 1 | 2021 | 726 | 0.040 |
Why?
|
Diabetes Complications | 1 | 2005 | 1320 | 0.040 |
Why?
|
Biology | 1 | 2020 | 292 | 0.040 |
Why?
|
Surgical Wound Dehiscence | 1 | 2019 | 216 | 0.040 |
Why?
|
Behavioral Risk Factor Surveillance System | 1 | 2019 | 211 | 0.040 |
Why?
|
Hepatectomy | 1 | 2021 | 588 | 0.040 |
Why?
|
Occult Blood | 1 | 2018 | 199 | 0.040 |
Why?
|
Evidence-Based Medicine | 1 | 2009 | 3709 | 0.040 |
Why?
|
Young Adult | 3 | 2021 | 60110 | 0.040 |
Why?
|
Chemokines | 1 | 2021 | 963 | 0.030 |
Why?
|
Proctocolectomy, Restorative | 1 | 2019 | 191 | 0.030 |
Why?
|
Drug Therapy | 1 | 2020 | 504 | 0.030 |
Why?
|
Veterans Health | 1 | 2018 | 216 | 0.030 |
Why?
|
Morbidity | 1 | 2022 | 1757 | 0.030 |
Why?
|
Myeloid Cells | 1 | 2021 | 840 | 0.030 |
Why?
|
Oligo-1,6-Glucosidase | 1 | 1995 | 7 | 0.030 |
Why?
|
Patients | 1 | 2023 | 908 | 0.030 |
Why?
|
Sucrase | 1 | 1995 | 51 | 0.030 |
Why?
|
Bone Morphogenetic Proteins | 1 | 2021 | 847 | 0.030 |
Why?
|
Age Distribution | 2 | 2019 | 2875 | 0.030 |
Why?
|
Patient Preference | 1 | 2023 | 947 | 0.030 |
Why?
|
Stromal Cells | 1 | 2021 | 1337 | 0.030 |
Why?
|
Predictive Value of Tests | 3 | 2020 | 15471 | 0.030 |
Why?
|
Immunity | 1 | 2021 | 1003 | 0.030 |
Why?
|
Confidence Intervals | 2 | 1998 | 2931 | 0.030 |
Why?
|
Thigh | 1 | 2016 | 239 | 0.030 |
Why?
|
Markov Chains | 1 | 2019 | 979 | 0.030 |
Why?
|
Cross-Sectional Studies | 3 | 2021 | 26384 | 0.030 |
Why?
|
Quality of Life | 3 | 2019 | 13510 | 0.030 |
Why?
|
Phagocytosis | 1 | 2020 | 1530 | 0.030 |
Why?
|
Dehydration | 1 | 2016 | 216 | 0.030 |
Why?
|
Biopsy | 2 | 1998 | 6805 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 1105 | 0.030 |
Why?
|
Colonic Polyps | 2 | 2000 | 557 | 0.030 |
Why?
|
Molecular Biology | 1 | 1998 | 573 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 3 | 2023 | 36861 | 0.030 |
Why?
|
Pyrimidines | 1 | 2006 | 3050 | 0.030 |
Why?
|
Insurance Claim Review | 1 | 2018 | 746 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 2 | 2019 | 6546 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2018 | 1839 | 0.030 |
Why?
|
Suture Techniques | 1 | 1999 | 779 | 0.030 |
Why?
|
Canada | 1 | 2019 | 2129 | 0.030 |
Why?
|
Time and Motion Studies | 1 | 2013 | 143 | 0.030 |
Why?
|
User-Computer Interface | 1 | 2000 | 1406 | 0.030 |
Why?
|
Herpesvirus 4, Human | 1 | 2019 | 1082 | 0.030 |
Why?
|
Carcinoembryonic Antigen | 2 | 1991 | 338 | 0.030 |
Why?
|
Prednisolone | 1 | 2014 | 327 | 0.030 |
Why?
|
Safety | 1 | 1998 | 1159 | 0.030 |
Why?
|
Colony Count, Microbial | 1 | 1993 | 328 | 0.030 |
Why?
|
Mice, SCID | 1 | 2018 | 2631 | 0.030 |
Why?
|
Electrolytes | 1 | 1993 | 279 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 1998 | 1737 | 0.030 |
Why?
|
Methods | 1 | 1993 | 1066 | 0.030 |
Why?
|
Probability | 1 | 1998 | 2483 | 0.030 |
Why?
|
Therapeutic Irrigation | 1 | 1993 | 297 | 0.020 |
Why?
|
Tumor Burden | 1 | 2018 | 1913 | 0.020 |
Why?
|
Sensitivity and Specificity | 4 | 2006 | 14751 | 0.020 |
Why?
|
Rectal Prolapse | 1 | 1992 | 33 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2019 | 1741 | 0.020 |
Why?
|
Thoracoscopy | 1 | 1993 | 186 | 0.020 |
Why?
|
Qualitative Research | 1 | 2023 | 3143 | 0.020 |
Why?
|
Cholangitis, Sclerosing | 1 | 1993 | 179 | 0.020 |
Why?
|
Reimbursement, Incentive | 1 | 2017 | 549 | 0.020 |
Why?
|
Administration, Topical | 1 | 2013 | 704 | 0.020 |
Why?
|
Minority Groups | 1 | 2019 | 1216 | 0.020 |
Why?
|
Liver Cirrhosis | 2 | 1999 | 1962 | 0.020 |
Why?
|
Abdominal Neoplasms | 1 | 1993 | 287 | 0.020 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 1995 | 1169 | 0.020 |
Why?
|
Reference Values | 1 | 1998 | 4941 | 0.020 |
Why?
|
Aftercare | 1 | 1997 | 921 | 0.020 |
Why?
|
Equipment Design | 1 | 1998 | 3529 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 2018 | 2395 | 0.020 |
Why?
|
Comorbidity | 1 | 2004 | 10591 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2014 | 1608 | 0.020 |
Why?
|
Efficiency, Organizational | 1 | 2013 | 699 | 0.020 |
Why?
|
Neutrophils | 1 | 2021 | 3785 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2021 | 3591 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2019 | 5323 | 0.020 |
Why?
|
Fever | 1 | 2016 | 1620 | 0.020 |
Why?
|
Immunocompromised Host | 1 | 2013 | 865 | 0.020 |
Why?
|
Polyethylene Glycols | 1 | 1993 | 1197 | 0.020 |
Why?
|
Insurance, Health | 1 | 2020 | 2518 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2006 | 9081 | 0.020 |
Why?
|
Male Urogenital Diseases | 1 | 2007 | 48 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2021 | 7609 | 0.020 |
Why?
|
Data Collection | 1 | 2017 | 3322 | 0.020 |
Why?
|
Ovarian Neoplasms | 1 | 2004 | 4919 | 0.020 |
Why?
|
Benchmarking | 1 | 2013 | 1058 | 0.020 |
Why?
|
Insurance Coverage | 1 | 2018 | 1946 | 0.020 |
Why?
|
Recovery of Function | 1 | 2017 | 2990 | 0.020 |
Why?
|
Body Mass Index | 1 | 2005 | 13054 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 4593 | 0.020 |
Why?
|
Poverty | 1 | 2019 | 2720 | 0.020 |
Why?
|
Blotting, Western | 1 | 2014 | 5035 | 0.020 |
Why?
|
Lipopolysaccharides | 1 | 2014 | 2222 | 0.020 |
Why?
|
Diagnostic Imaging | 2 | 1998 | 3538 | 0.020 |
Why?
|
Unnecessary Procedures | 1 | 2009 | 419 | 0.020 |
Why?
|
Sex Factors | 1 | 2020 | 10641 | 0.020 |
Why?
|
Surgical Procedures, Operative | 1 | 1997 | 1941 | 0.020 |
Why?
|
Computer Simulation | 1 | 2019 | 6289 | 0.020 |
Why?
|
Methylhydrazines | 1 | 1984 | 6 | 0.020 |
Why?
|
Dimethylhydrazines | 1 | 1984 | 12 | 0.020 |
Why?
|
Intraoperative Period | 1 | 2006 | 513 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2020 | 10486 | 0.010 |
Why?
|
Societies, Medical | 1 | 2017 | 3967 | 0.010 |
Why?
|
Glucocorticoids | 1 | 2014 | 2167 | 0.010 |
Why?
|
Catheterization, Central Venous | 1 | 2009 | 536 | 0.010 |
Why?
|
Device Removal | 1 | 2009 | 643 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2014 | 3233 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2021 | 10276 | 0.010 |
Why?
|
Fallopian Tubes | 1 | 2004 | 179 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2013 | 6320 | 0.010 |
Why?
|
Patient Discharge | 1 | 2016 | 3490 | 0.010 |
Why?
|
Risk Assessment | 2 | 2019 | 24330 | 0.010 |
Why?
|
Blood Transfusion | 1 | 2009 | 1309 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2018 | 14485 | 0.010 |
Why?
|
Mass Screening | 1 | 2018 | 5455 | 0.010 |
Why?
|
Carcinogens | 1 | 1984 | 453 | 0.010 |
Why?
|
Ovariectomy | 1 | 2004 | 615 | 0.010 |
Why?
|
Cell Movement | 1 | 2014 | 5216 | 0.010 |
Why?
|
Placebos | 1 | 2006 | 1668 | 0.010 |
Why?
|
Inflammation | 1 | 2021 | 10869 | 0.010 |
Why?
|
Gene Expression | 1 | 2014 | 7602 | 0.010 |
Why?
|
Carcinoma, Hepatocellular | 1 | 1994 | 2336 | 0.010 |
Why?
|
Antiviral Agents | 1 | 2013 | 3069 | 0.010 |
Why?
|
Registries | 1 | 1997 | 8384 | 0.010 |
Why?
|
Evaluation Studies as Topic | 2 | 1994 | 1629 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2006 | 3438 | 0.010 |
Why?
|
Ovary | 1 | 2004 | 965 | 0.010 |
Why?
|
International Cooperation | 1 | 2006 | 1436 | 0.010 |
Why?
|
Quality Assurance, Health Care | 1 | 2009 | 2181 | 0.010 |
Why?
|
Gastrointestinal Diseases | 1 | 2007 | 1206 | 0.010 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 1984 | 977 | 0.010 |
Why?
|
Adolescent | 3 | 2006 | 89247 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2014 | 19023 | 0.010 |
Why?
|
Prostate-Specific Antigen | 1 | 2007 | 2487 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2006 | 6242 | 0.010 |
Why?
|
Signal Transduction | 1 | 2020 | 23652 | 0.010 |
Why?
|
Mutation | 1 | 2021 | 30266 | 0.010 |
Why?
|
Age of Onset | 1 | 2004 | 3346 | 0.010 |
Why?
|
Diagnosis, Differential | 2 | 2004 | 13020 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2000 | 20776 | 0.010 |
Why?
|
Intestinal Polyps | 1 | 1995 | 105 | 0.010 |
Why?
|
Neoplasm, Residual | 1 | 1997 | 1019 | 0.010 |
Why?
|
Hyperplasia | 1 | 1995 | 1154 | 0.010 |
Why?
|
Laparotomy | 1 | 1994 | 459 | 0.010 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 1984 | 3116 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2013 | 13699 | 0.010 |
Why?
|
Sex Distribution | 1 | 1995 | 2280 | 0.010 |
Why?
|
Palliative Care | 1 | 2004 | 3644 | 0.000 |
Why?
|
Folic Acid | 1 | 1995 | 1336 | 0.000 |
Why?
|
Animals | 2 | 2018 | 169408 | 0.000 |
Why?
|
Lung Neoplasms | 1 | 1991 | 13593 | 0.000 |
Why?
|
Cell Transformation, Neoplastic | 1 | 1995 | 2848 | 0.000 |
Why?
|
1,2-Dimethylhydrazine | 1 | 1984 | 8 | 0.000 |
Why?
|
Rats, Inbred WF | 1 | 1984 | 140 | 0.000 |
Why?
|
Stomach Neoplasms | 1 | 1993 | 1483 | 0.000 |
Why?
|
Immunohistochemistry | 1 | 1995 | 11119 | 0.000 |
Why?
|
Alcohol Drinking | 1 | 1995 | 4045 | 0.000 |
Why?
|
Neoplasms, Experimental | 1 | 1984 | 1231 | 0.000 |
Why?
|
Recurrence | 1 | 1991 | 8512 | 0.000 |
Why?
|
Liver | 1 | 1994 | 7579 | 0.000 |
Why?
|
Smoking | 1 | 1995 | 9094 | 0.000 |
Why?
|
Prevalence | 1 | 1995 | 15875 | 0.000 |
Why?
|
Diet | 1 | 1995 | 8090 | 0.000 |
Why?
|
Rats | 1 | 1984 | 23847 | 0.000 |
Why?
|
Antibodies, Monoclonal | 1 | 1984 | 9264 | 0.000 |
Why?
|
Phenotype | 1 | 1984 | 16735 | 0.000 |
Why?
|